Rating: Neutral | Target Price: RMB 40-46 (base-case fair value range) | Current Price: RMB 41.37 (close on 2026-10-30) | Time Horizon: 6-12 months
Pharmaron's fundamental inflection is real: revenue for the first three quarters of 2026 was RMB 12.003 billion (+19.0%), adjusted Non-IFRS net profit attributable to shareholders RMB 1.496 billion (+22.0%), new orders up more than 30% YoY (CDMO +40%+, Top 20 pharma revenue +52.5%), and after management raised full-year guidance from 12-18% to 15-20% within the year, the first three quarters landed in the upper half of that range. But the current price of RMB 41.37 has already paid in full for "smooth delivery of the base case": TTM adjusted PE of 36.4x and PB of 4.52x (nearly identical PB to WuXi AppTec despite ROE at roughly half its level). Reverse DCF implies the current price embeds a +22-24% FCFE CAGR over the next five years, whereas the company's FY2023→FY2025 non-GAAP net profit CAGR was only +0.8% — the market is pricing a nascent inflection as if it were a "five-year undiminished trend." We estimate base-case fair value at RMB 40-46, essentially overlapping the current price, with no substantive margin of safety; downside to the bear case (impact of the US BCC list plus cooling biotech funding) is -47%~-57%, upside to the bull case (commercialization delivery of Lilly's oral GLP-1) is +16%~+38%, making the risk-reward neutral to slightly unfavorable. Two quality-related constraints run through this report: earnings quality (ROIC ~7.1% below the 8-9% cost of capital, FCF of -RMB 299 million for the first three quarters, goodwill of RMB 3.483 billion representing 20.6% of net assets attributable to shareholders) and the binary policy event of the OMB "Biosecure Concerned Company" (BCC) list due before December 18, 2026.
The most important changes over the next 6-12 months (evidence grade A): First, whether the 2026 revenue guidance (15-20%) delivers at its upper bound and the quality of 2027 guidance, to be resolved at the annual report window (2027-03); Second, progress of orforglipron (Lilly's oral small-molecule GLP-1, FDA-approved 2026-04) through China NMPA review — Pharmaron provides commercial formulation manufacturing for its China business, and the window for the partnership to move from "capacity placement" to "revenue recognition" is 2026Q4-2027H2; Third, the BCC list under the BIOSECURE Act is due by the statutory deadline of 2026-12-18, and the geopolitical discount that has weighed on the sector for two years could see a phase of clearing — but the probability of a list delay cannot be ignored (see C4).
Primary share-price driver: Order and demand momentum. Quarterly new-order growth (first three quarters +30%+), Top 20 pharma revenue growth (+52.5%), and North America revenue growth (+10.1%) are three directly trackable leading indicators; note, however, that historically Pharmaron's order growth and the following year's revenue growth have twice inverted (2024 CDMO new orders +35% translated into 2025 segment revenue +16.5%; ~+13% new orders in 2025 corresponded to +31.7% in the first three quarters of 2026) — delivery timing, not order growth, drives revenue recognition, so extrapolating revenue from new-order data requires a discount.
Verifiable expectation gaps: No positive expectation gap. Sell-side consensus (27 brokers) for FY2027E EPS is RMB 1.41 (+31.8%) with a median target price of RMB 58.0, versus the current price of only RMB 41.37 — the Street is more optimistic than we are; reverse DCF shows the current price already demands five years of +22-24% earnings compounding. Better entry opportunities will most likely come from pullbacks: potential triggers include delays in or pre-listing back-and-forth on the BCC list, the unlock of shares acquired via the April 2027 negotiated transfer, and Fed tightening pressuring biotech funding.
Validation and falsification: Catalysts — BCC list in 2026-12, Q4 earnings preannouncement in 2027-01, annual report and 2027 guidance in 2027-03, orforglipron approval in China, commissioning of the solid-phase peptide synthesis plant. Falsification conditions — Pharmaron added to the BCC/1260H list; two consecutive quarters of negative growth in North America client revenue; new-order growth falling below +10%; combined gross margin of Labs+CDMO falling below 30%; goodwill impairment provisions exceeding RMB 500 million.
The momentum is real: guidance was raised within the year from 12-18% to 15-20%; the first three quarters grew +19.0% and Q3 accelerated to +20.9%; European clients +30.1%, mainland China clients +39.1%; clients engaging multiple business units accounted for 73.61% of revenue (2026H1). But two discounts must be stated: First, the "good guidance delivery record" holds only for the 2025-2026 industry recovery period — there was a clear miss in 2024. Second, the add-backs in the adjusted Non-IFRS measure ballooned from RMB 86 million in the prior-year period to RMB 249 million (+190%); the three new add-back categories in 2026 (amortization of intangible assets from acquisitions, one-off restructuring costs, and convertible bond expenses) imply a like-for-like recomputed growth of roughly +19% rather than +22% — momentum is unchanged, but the widest measure's headline growth rate contains some cosmetic elements. The order-to-revenue conversion rate is not historically calibrated (the two inversions noted above), and new orders are an unaudited company-disclosed metric with no absolute amounts disclosed.
This is Pharmaron's CDMO segment's first foray into commercial formulation manufacturing for a global blockbuster product — strategically significant. But three facts constrain its weight in current valuation: ① Lilly's initial USD 200 million is an equity injection and technology-capability commitment, not confirmed orders — no disclosed revenue amounts, minimum purchase volumes, or capacity guarantee terms to date (Goldman Sachs' 2026-03-12 report likewise noted order size was pending disclosure); ② orforglipron's China NMPA application was only accepted in 2026-01 and not yet approved, and Lilly's China supply chain follows a "Suzhou self-build + multiple local partners" model in which Pharmaron is not exclusive — formulation processing fees are typically only a low-single-digit percentage of drug sales; ③ the true primary driver of the first-three-quarter CDMO +31.7% is concentrated late-funnel project deliveries (process validation/commercial projects rising from 34 at end-2025 to 45 in 2026H1), not GLP-1. Another figure overlooked by most narratives: the total small-molecule CDMO project funnel fell from 1,102 at end-2025 to 782 in 2026H1 (-29%, mainly preclinical 750→448); the company did not explain the change in scope, and whether early-funnel replenishment is shrinking needs to be verified in the annual report. No sell-side deep-dive report, even the most bullish, matches a 30% CAGR for the segment over 2026-2028; we treat this as a "marginal upside option" rather than a "segment-level primary driver."
ROIC of ~7.1% (calculated in this report as FY2025 after-tax operating profit over interest-bearing debt plus equity attributable to shareholders) sits below the 8-9% WACC range; expansion-phase returns are being diluted. Deductible losses underlying unrecognized deferred tax assets rose from RMB 2.665 billion to RMB 4.171 billion, pointing to persistent losses at some subsidiaries. The other side must be fairly presented: the surge in prepayments and inventories was accompanied by contract liabilities +27.5% (RMB 961 million → 1.225 billion), pointing to order-driven stockpiling rather than deteriorating collections; FY2025 full-year FCF was positive at RMB 552 million with OCF/net profit of 1.94; Q3 standalone CDMO gross margin 31.1% (+3.9pct QoQ) and clinical gross margin 13.1% (+2.3pct YoY) already show signs of repair. Conclusion: the earnings-quality strain is a combination of "expansion-phase reinvestment + stockpiling" and "structurally insufficient returns"; the 2026 annual report is the watershed — if FCF is negative for a second consecutive year and inventory turns deteriorate, it becomes a structural problem; if CapEx converges within the RMB 3 billion guidance and inventory clears with commercial deliveries, it is cyclical reinvestment.
We assign a tripartite probability to the list's path: on-time publication without Pharmaron ~0.55; Pharmaron included ~0.10; delay/watering down/phased rollout ~0.35 — market predictions of geopolitical legislative timing have been wrong for two consecutive years, and treating "December clearing" as a certainty is dangerous. Pharmaron has never been named in any version historically and is not on the 1260H list as expanded in 2026-06 (188 companies; WuXi is listed but obtained a preliminary court injunction in August), so inclusion probability is indeed low; but even without naming, "soft biosecurity" (tightened US client due diligence, marginal order shifting) is slowly occurring. The +10.1% North America growth should be read objectively: 2024H1 was -0.2%, 2025H1 +11.0% — the current level is a post-recovery plateau; over the same period WuXi AppTec, with a higher US revenue share, raised guidance twice within the year (no systematic deterioration in North America demand), and Pharmaron's weaker North America growth more likely reflects its small/mid-cap biotech client mix. It is a quarterly tracking point, not a confirmed deterioration signal.
Three implications of the valuation structure: ① The current price nearly coincides with the most cautious sell-side tier (Huachuang RMB 41 / Goldman Sachs RMB 38.5) and is ~29% below the consensus median of RMB 58 — market pricing is clearly stratified; the current price corresponds to "base-case delivery," while optimists are already bidding for the bull scenario; ② PB of 4.52x is on par with WuXi AppTec (4.45x) despite ROE at roughly half its level (TTM annualized ~10.4% vs 22-28%) — the PB-ROE pairing is expensive, with the entire premium staked on gross-margin repair; ③ reverse DCF implies +22-24% FCFE compounding over the next five years (cost of equity 9.0-9.5%, perpetual growth 3.5%), effectively linearly extending current order momentum for five years — whereas the non-GAAP FY2023→FY2025 CAGR was only +0.8% (a period spanning the biotech funding downturn). The A-share trades at a ~81% premium to the H-share (~20x TTM adjusted PE); this is a structural spread driven by investor structure and liquidity, with the H-share additionally pressured by potential convertible bond conversion supply — it is not evidence of A-share over- or undervaluation, only a cross-market reference.
| Metric | FY2023 | FY2024 | FY2025 | 2026Q1-3 |
|---|---|---|---|---|
| Operating revenue (RMB 100M) | 115.38 | 122.76 | 140.95 | 120.03 |
| YoY | — | +6.39% | +14.82% | +19.01% |
| Net profit attributable to shareholders (RMB 100M) | 16.01 | 17.93 | 16.64 | 12.47 |
| YoY | — | +12.01% | -7.22% | +9.31% |
| Non-GAAP net profit attributable (RMB 100M) | 15.14 | 11.08 | 15.38 | 11.81 |
| Adjusted Non-IFRS net profit attributable (RMB 100M) | 19.03* | 16.07 | 18.16 | 14.96 |
| Gross margin | 35.75% | 34.24% | 34.83% | 32.92% |
| Net margin attributable to shareholders | 13.88% | 14.61% | 11.80% | 10.39% |
| Net operating cash flow (RMB 100M) | 27.54 | 25.77 | 32.21 | 19.07 |
| Free cash flow (RMB 100M, OCF-CapEx) | -1.12 | 5.36 | 5.52 | -2.99 |
| Cash + cash-like assets (RMB 100M, period-end) | — | 34.43 | 29.91 | 54.74 |
| Interest-bearing debt-borrowings basis (RMB 100M, period-end) | — | 55.74 | 66.61 | 70.45 |
| Goodwill (RMB 100M, period-end) | — | 27.75 | 35.86 | 34.83 |
| Debt-to-asset ratio | — | 40.56% | 41.91% | 45.44% |
| Net debt/EBITDA | — | — | ~1.09 | Net debt RMB 3.739 billion |
*FY2023 adjusted figure is back-calculated from the YoY decline disclosed in 2024. At end-2026Q3 there were additionally lease liabilities of RMB 421 million and the liability component of a zero-coupon convertible bond maturing in 2027 of RMB 2.168 billion (total interest-bearing debt including these two items: RMB 9.634 billion); cash-like assets = monetary funds + trading financial assets + fixed-income wealth management products (excluding restricted funds).
Reasons for metric changes (YoY ≥±20% excerpts): ① The FY2025 divergence of -7.22% attributable profit vs +38.85% non-GAAP profit — the company explained it as large investment gains from the prior-year disposal of its PROTEOLOGIX equity stake (2024 non-recurring gains/losses of RMB 685 million); ② First-three-quarter operating cash flow -21.73% — the company provided no official attribution in its periodic report; statement drivers were cash paid for goods +58.0%, inventories +49.74% (company explanation: increased raw materials and contract fulfillment costs), prepayments +1041.52% (company explanation: prepaid inventory purchase payments), tax refunds -19.9%, moving in tandem with contract liabilities +27.5%, pointing to order-driven stockpiling; ③ Finance expenses +100.98% — the company explained it as mainly increased FX losses YoY (Non-IFRS FX-related losses RMB 169 million vs RMB 31 million in the prior-year period); ④ Investment income +218.79% — the company explained it as increased investment income from associates; ⑤ Non-current liabilities due within one year +739.14% at end-2025 — the company explained it as partial reclassification of long-term borrowings to due within one year.
First-three-quarter revenue was RMB 12.003 billion (+19.01%), with Q3 standalone at RMB 4.408 billion (+20.94%), accelerating for two consecutive quarters; attributable profit of RMB 1.247 billion (+9.31%) lagged revenue, while non-GAAP at RMB 1.181 billion (+14.20%) and adjusted at RMB 1.496 billion (+21.97%) strengthened progressively — the differences mainly stem from FX (finance expenses RMB 308 million, +100.98%) and fair value/investment gains and losses; on an operating basis, profit growth actually outpaced headline attributable profit. By segment: Lab Services RMB 7.222 billion (+15.0%, gross margin 40.23%, -2.4pct YoY on RMB appreciation squeezing prices); CDMO RMB 3.102 billion (+31.7%, gross margin 27.83%, +2.1pct YoY); Clinical Research RMB 1.659 billion (+15.2%, gross margin 10.96%, with Q3 standalone at 13.1% showing a signal of an inflection in domestic price competition). Regional structure diverged sharply: mainland China +39.09%, Europe +30.07% (large late-stage project deliveries recognized), North America +10.10%. Relative to sell-side consensus (FY2026E attributable profit RMB 1.966 billion), the first three quarters delivered 63% of attributable and ~68% of adjusted (against FY2026E RMB 2.19 billion) — both on a normal track. Gross margin -1.3pct YoY and OCF -21.7% are two blemishes: the former has an FX explanation, while the latter carries no official attribution from the company. Overall: a results report that confirms strong momentum but with flawed profit-quality details; the market's same-day reaction was mildly positive.
Model in brief: A labor-intensive integrated CRDMO — front-end laboratory services (drug discovery chemistry + biology, ~60% of revenue, labor-driven) + back-end small-molecule CDMO (process development and API/formulation production, ~26%, capital-intensive expansion underway) + clinical CRO/SMO (~14%, asset-light) + biologics and CGT (merged into the CDMO segment from 2026Q2, still in incubation). Revenue is essentially project-based service fees; overseas revenue accounts for 84.84% (FY2025), with 89.84% delivered from within China; revenue from existing customers accounts for 98.19%, and multi-segment cross-selling customers 73.61% — strong integration stickiness, but limited bargaining power with any single customer (top five customers account for 16.05%). The asset-light side shows signs of pricing power (laboratory gross margin 40%+), while the asset-heavy side's gross margin climbs with capacity utilization (CDMO 27.8% → 31.1% for Q3 alone).
Cash content of earnings: OCF/net profit attributable to parent was 1.72 / 1.44 / 1.94 for FY2023-FY2025, and 1.53 for the first three quarters — excellent collection quality, consistently above the 0.8 health threshold; but FCF/net profit attributable to parent was -0.07 / 0.30 / 0.33 / -0.24 (first three quarters), with the bulk of book profit continuously consumed by capex; 2026 CapEx guidance exceeds RMB 3 billion (RMB 2.206 billion already invested in the first three quarters). Recurring-basis check: of FY2024's RMB 1.793 billion attributable net profit, RMB 685 million came from one-off disposal gains (38%), so the recurring figure of RMB 1.108 billion is the true operating center for that year — using the attributable basis for a three-year trend would be severely distorted. Reverse-checking the looseness of the company's self-reported adjusted basis: add-backs expanded from RMB 86 million in the same period of 2025 to RMB 249 million for the first three quarters (+190%); in 2026 three new categories were added — intangible asset amortization (RMB 21 million), one-off restructuring costs (RMB 34 million), and convertible bond fees (RMB 3 million) — of which restructuring costs and acquisition amortization have a recurring character. Recalculating on this stricter basis, adjusted growth for the first three quarters is roughly +19% rather than +22%, and TTM adjusted PE correspondingly higher: the widest point of the definition is precisely where valuation is most sensitive. SBC add-back of RMB 48 million is still small in absolute terms.
Return on capital: ROIC of ~7.1% (FY2025 estimate) is below WACC of 8-9% — incremental capital returns during the expansion phase have not yet crossed the cost of capital line; corresponding weighted ROE 7.59% (-0.46pct). This is the dividing-line metric between "real growth" and "pseudo-growth"; whether it can break above 10% after capacity ramp-up in 2027 is the key observation.
Capex quality: CapEx/D&A was 1.78 in FY2024 and 2.10 in FY2025; the company does not split maintenance vs. growth capex. Spending is identifiable as growth-oriented (Shaoxing Phase II, solid-phase peptide synthesis workshop, Hangzhou CDMO workshop, Beijing third-campus laboratory expansion); the Ningbo API facility passed FDA on-site inspections twice in 2025-2026 and in 2026H1 passed the company's first Pre-Approval Inspection (PAI) for a China-innovated API — capacity qualifications match the order funnel. The risk is the race between the incremental depreciation from RMB 3 billion+ of capex (estimated RMB 500-800 million per year) and the ramp-up in utilization.
Red flags: ① Marginal positive/turning negative free cash flow while 2026 capex accelerates again; ② ROIC below cost of capital; ③ Goodwill of RMB 3.483 billion, 20.6% of net assets attributable to parent (2025 acquisitions added RMB 811 million; the UK asset group has a prior impairment record); ④ Slight decline in per-capita output (FY2024 ~RMB 574,000 → FY2025 ~RMB 562,000; headcount 21,370 → 25,088); ⑤ Minority shareholders continuously absorbing losses from incubating segments (FY2023-25: -RMB 193 million / -792 million / -1.087 billion; first three quarters -RMB 38 million, narrowing YoY).
Consistency of words and deeds: partially delivered. The 2026 revenue guidance was raised from 12-18% to 15-20% and the upper half (+19.0%) was delivered in the first three quarters; the presentation explicitly expressed "full confidence" — on track; but 2024 offers a clear counterexample (at the June 2024 AGM the company maintained guidance of "revenue growth over 10%" while the full year actually grew +6.39%, a miss of ~3.6pct, with no formal review by the company). The 2023-2024 annual reports contained no quantified revenue guidance commitments, so the verifiable sample is limited. Overall judgment: pragmatic and initially conservative, revised upward with orders, but the sample supporting "reliable guidance" covers only two years of industry recovery.
Shareholder friendliness: neutral, expansion first. Dividends of RMB 2 per 10 shares for three consecutive years (FY2025 payout of RMB 366 million, 22.0% payout ratio, ~0.48% dividend yield at current price); in 2024 repurchased RMB 200 million of A-shares for cancellation and additionally repurchased 7.26 million H-shares for treasury. But financing is equally active: in 2026H1 a placement of new H-shares raised RMB 1.185 billion; in September issued RMB 2.18 billion of zero-coupon convertible bonds (net ~RMB 2.221 billion, conversion price HKD 36.08, potential dilution ~3.8%); and established an H-share award trust with a 28 million share limit — "dual equity-debt financing plus mild dilution" during expansion; dividends and buybacks are a drop in the bucket relative to CapEx.
Risk signals: The controlling family holds ~17.5%, of which Lou Xiaoqiang's personal pledge ratio is 47.9% (family-wide pledges ~13.2% of holdings, being unwound continuously; the company discloses no margin-call risk); Pharmaron Holdings (an overseas platform related to the controllers) block-sold 18.373 million A-shares in October 2026 for RMB 715 million (RMB 38.89/share, institutional buyers with a 6-month lock-up); PE shareholder CITIC (still holding 10.76%) has been selling in multiple tranches since December 2025; related-party transactions are minimal (actual 2025 transactions with Ningbo Xinwan Technology of RMB 32.26 million, 0.23% of revenue). Overall: no malign signals, but shareholders and related parties constitute a persistent, mild supply overhang.
| Segment | Revenue (RMB 100M) | Share | YoY | Gross margin | Gross profit contribution* | Business logic in one line |
|---|---|---|---|---|---|---|
| Laboratory Services | 72.22 | 60.2% | +15.0% | 40.23% (-2.4pct) | 73.5% | Labor-driven cash cow and traffic gateway; biology >60% of mix, funneling to back-end |
| CDMO Services (incl. former biologics/CGT CDMO) | 31.02 | 25.8% | +31.7% | 27.83% (+2.1pct) | 21.9% | Capital-intensive; orders +40%+; late-clinical and commercial projects ramping, capacity tight |
| Clinical Research Services | 16.59 | 13.8% | +15.2% | 10.96% (-0.8pct) | 4.6% | Asset-light, labor-based; domestic price competition at an inflection (Q3 alone 13.1%) |
| Biologics & CGT (old definition, merged into CDMO from 2026Q2) | FY2025: 4.75 | 3.4% | +16.48% | -40.31% (FY2025, improved 9.76pct) | — | Continuous loss reduction during build-out; no longer reported separately from 2026 |
*Gross profit contribution = revenue × gross margin / total gross profit (segment gross profit totaled RMB 3.951 billion for the first three quarters; our estimate).
Unsurprisingly, the profit engine is Laboratory Services: 73.5% of gross profit on 60.2% of revenue; the growth engine is CDMO (+31.7%). The 29.3pct gross margin gap (40.23% vs 10.96%) must be highlighted: laboratory work is a chemist-capacity business with high per-head output and pricing power; clinical research is essentially labor outsourcing plus hospital channels, with many domestic competitors and centralized procurement pressuring prices — gross margin has declined steadily over four years from 17.05% → 12.82% → 11.41% → 10.96%. The integrated platform's value lies in front-end funneling and customer stickiness, not in the clinical segment's own profitability. The 2026 segment redefinition (biologics/CGT CDMO portion merged into CDMO, discovery portion into Laboratory) reduces year-over-year comparability; this table follows the new definitions.
Accounting red flags (by severity):
Cross-period consistency checks: ① Attributable vs. recurring growth divergence — consistent with the company's explanation (disposal-gain base); ② OCF vs. profit divergence (OCF/attributable 1.44 → 1.94 → 1.53; 2026 OCF -21.7% while revenue +19.0%) — unexplained by the company (the interim report's statement of changes notes "no material changes"), a disclosure gap; ③ Four consecutive years of clinical gross margin decline — consistent with management's explanation of "order mix changes + domestic competition," with a Q3 inflection noted; ④ CapEx pulse vs. thin long-run FCF — consistent (a deliberate expansion-strategy choice); ⑤ FX impact reversing direction (finance costs RMB 53 million → 143 million → 156 million → 308 million for the first three quarters) — consistent with the RMB appreciation explanation. Overall judgment: no signs of systematic earnings manipulation; the main issues are two disclosure blemishes — expanding adjusted-basis add-backs and the absence of official attribution for the OCF deterioration.
Current market data and multiples: Share price RMB 41.37 (close of 2026-10-30), market cap RMB 76.008 billion, total shares 1.837 billion. PE(TTM) on three bases: attributable 42.9x (68th percentile over five years — this basis's earnings are unrepresentative (includes 2024 one-off gains); the percentile is for reference only), recurring 45.1x, adjusted Non-IFRS 36.4x; PS(TTM) 4.75x; PB 4.52x (57th percentile over five years, 80th percentile over one year). Average daily turnover ~RMB 1.67 billion (2.2% of market cap) — ample liquidity.
Peer comparison (data as of 2026-10-31):
| Company | PE (TTM) | PB | Revenue growth | ROE | Key differences vs. Pharmaron |
|---|---|---|---|---|---|
| Pharmaron | 45.1x (recurring) / 36.4x (adjusted) | 4.52x | 9M26 +19.0% | TTM annualized ~10.4% | Strong front-end discovery, back-end commercialization just starting |
| WuXi AppTec | 21.3x (recurring TTM) / 16.3x (attributable, distorted) | 4.45x | 9M26 +38.6% | FY2025 27.69% | 3.5x the scale, ~21pct higher gross margin, TIDES at RMB 10B+ level |
| Asymchem | 41.1x | 2.74x | 9M26 +16.5% | FY2025 6.57% | Pure CDMO, world #2 in peptide capacity, backlog +53.8% |
| Tigermed | 47.8x (static, distorted by fair-value drag) | 2.16x | 9M26 +15.2% | FY2025 4.27% | Pure clinical CRO, profitability highly cyclical |
(Note: PE bases differ across companies — WuXi/Pharmaron recurring TTM, Asymchem attributable TTM, Tigermed static — for cross-company comparison rely on PB-ROE and adjusted figures.)
Market-implied expectations: The current price ≈ 40x normalized FCFE (adjusted basis, ~RMB 1.9 billion); reverse-engineering a two-stage DCF, the current price requires FCFE to compound at +22-24% over the next five years (cost of equity 9.0-9.5%, terminal growth 3.5%). Against reality: current momentum of 9M26 adjusted +22% and orders +30%+ matches, but FY2023→FY2025 recurring CAGR was only +0.8% (including disruption from the financing downturn) — the current price requires Pharmaron to sustain a "three-quarter-old inflection" for five consecutive years, with no margin for execution hiccups. In one sentence: the price demands "+22% momentum without decay," while the reality is genuine momentum but very high historical variance.
Three-tier value (EPV): Asset value ~RMB 9.19/share (book value per share; ~RMB 7.30 after excluding RMB 3.483 billion of goodwill) — a replacement-cost reference, not support; EPV with zero growth ~RMB 11.44/share (normalized FCFE ~RMB 1.03/share ÷ 9.0% cost of equity; bridge: FY2026E adjusted attributable profit RMB 2.19 billion + D&A RMB 1.27 billion - maintenance CapEx RMB 1.27 billion - working capital changes ~RMB 150 million, cross-checked against the cash method with a midpoint of RMB 1.9 billion; the growth portion of the RMB 3 billion+ CapEx and planned capacity are all assigned to future scenarios and excluded from the zero-growth tier); the residual of current price over EPV (the growth option) is ~72.3% of the price (system-computed on a consistent basis). Two misreadings must be avoided: a 72% option share does not mean overvaluation — CXO is in an order upcycle with a gross-margin inflection, and paying for growth has industrial logic; but it means the downside lacks a dual floor of earnings and assets — any loss of momentum (policy shock / order attrition / gross margin failing to recover) would simultaneously puncture both the growth layer and the multiple. Moreover, if the RMB 2.18 billion convertible bonds are fully converted, net debt falls from RMB 3.74 billion to ~RMB 1.6 billion — the capital structure has a two-way path.
Three scenarios and odds (12-18 month horizon):
| Scenario | Probability | Fair range | vs. current price | Core assumptions and swing factors |
|---|---|---|---|---|
| Bear | 0.22 | RMB 18-22 | -57%~-47% | BCC list naming or biosecurity sentiment escalation + Fed tightening pressuring financing: 2027 revenue growth slows to +3%, adjusted net margin stuck at 12% (~RMB 2.04 billion) × 16-20x; the most conservative external targets (Huachuang RMB 41 / Goldman Sachs RMB 38.5) all assume normal operations and exclude policy shocks — not comparable to this scenario and not adopted as the lower bound |
| Base | 0.51 | RMB 40-46 | -3%~+11% | 2026 guidance delivered (~RMB 16.5 billion), 2027 revenue +15% to RMB 19.0 billion, adjusted net margin recovering to 14.0% (~RMB 2.67 billion) × 28-32x 2027E; multiple anchor: discount to the company's five-year median PE of 35x plus the A-share CXO peer band (WuXi recurring 21.3x / Asymchem 41.1x, a 30-40x band), cross-checked with PEG≈1.3 — current-price multiple not used |
| Bull | 0.27 | RMB 48-57 | +16%~+38% | GLP-1 commercial formulation ramp + peptide/ADC capacity ramp-up delivered: 2028E adjusted RMB 3.1-3.3 billion (2027-28 CAGR 22-25%) × 30-35x exit, discounted one year (9.5%); anchor: comparable companies in their growth-delivery phase (Asymchem at its +53.8% order stage traded at 40x+) with a discount to Pharmaron for earnings quality and capital intensity |
House earnings forecasts (alongside management guidance and sell-side consensus): FY2026 revenue RMB 16.2-16.9 billion (+15-20%, per guidance range; management guides 15-20%, consensus implies a midpoint of RMB 16.5 billion); attributable RMB 1.85-1.95 billion (+11-17%), adjusted RMB 2.15-2.25 billion (+18-24%) — 0-6% below sell-side consensus FY2026E attributable of RMB 1.966 billion, as we are more cautious on FX and fair-value items. FY2027 revenue RMB 18.6-19.6 billion (+13-17%), attributable RMB 2.25-2.50 billion, adjusted RMB 2.55-2.75 billion — 3-13% below consensus FY2027E of RMB 2.59 billion; the divergence lies in the slope of gross-margin recovery (we assume adjusted net margin 13.5-14.0%; the Street is steeper).
Conclusion: Fair. Target price range RMB 40-46 (base-case fair value), safety margin of ~-3.3% (base-case floor RMB 40 vs. current price RMB 41.37) — separating quality from price: quality is on an improving path (orders, gross-margin inflection, and the GLP-1 option are all real), but the price already fully capitalizes the base-case recovery; the current price is neither significantly undervalued nor visibly bubbly, with expected return of ~-2% and an odds structure more sensitive to the downside. Sensitivity check on the adjusted basis: if the three newly added 2026 add-backs (restructuring costs / acquisition amortization / convertible bond fees) are excluded, TTM adjusted PE rises to ~38-39x, strengthening rather than weakening the "no margin of safety" conclusion.
Industry size. The global CXO (drug discovery CRO + clinical CRO + CDMO) market was approximately USD 147.6 billion in 2022, and Frost & Sullivan projects it to reach about USD 275 billion by 2027 (drug discovery USD 35.9 billion, clinical CRO USD 81.8 billion, CDMO USD 157.3 billion), implying a five-year CAGR of roughly 13.3%—by segment: CDMO 16.0% > drug discovery 14.8% > clinical CRO 8.4%. China's small-molecule CDMO market was about RMB 85.9 billion in 2023, with a recent CAGR of about 19.4% (F&S); China's preclinical CRO market is estimated at about RMB 52.9 billion by 2026E, and domestic clinical CRO at about RMB 95.6 billion by 2030E (2024-2030 CAGR ~13%, F&S). The industry's growth history has gone through a clear downturn and recovery: 2022-2024 saw declining financing and COVID order rundown, with global leaders' growth falling to single digits (WuXi 2024 -2.7%, Pharmaron +6.4%); from 2025 growth broadly returned to double digits (WuXi +15.8%, Pharmaron +14.8%), and 2026 guidance at the leaders was revised further upward (WuXi +35-39%, Asymchem +19-22%, Pharmaron +15-20%).
Structural demand increment—the quantified peptide/GLP-1 chain. This is currently the strongest exogenous variable driving CXO demand repricing: the global peptide drug market was USD 89.5 billion in 2023 → ~USD 261.2 billion by 2032E (CAGR 12.6%, F&S via TEDD Pharmaceutical prospectus); tirzepatide H1 2026 sales were USD 27.69 billion (+88%, Huaxin Securities); Eli Lilly's oral GLP-1 orforglipron was approved by FDA on 2026-04-01 (LillyDirect pricing USD 149-399/month), with consensus peak sales expectations above USD 20 billion (Guosheng Securities), and Lilly launched a "USD 3 billion over ten years" supply chain investment in China. The jump in unit economics is real: peptide solid-phase synthesis has low yields and purification accounts for 50%+ of total cost, so the capacity and outsourcing value per unit of sales far exceed traditional small molecules—manifesting as a global peptide solid-phase synthesis capacity arms race (WuXi reactors exceed 100,000 liters; Asymchem 45,000 liters → 69,000 liters by end-2026; Samsung Biologics acquired Polypeptide for CHF 1.46 billion in 2026-10; Pharmaron's peptide API solid-phase synthesis workshop to be completed in 2026). Demand-side penetration is still climbing: Morgan Stanley projects the global obesity drug market to reach USD 150 billion by 2035, with oral formulations removing cold-chain requirements and opening grassroots accessibility. For Pharmaron, it is one of the positioned players in this increment (the only formulation CDMO named by Lilly in China, with an initial USD 200 million injection), but the company-level magnitude evidence chain is not yet closed (contract amounts undisclosed)—the structural direction is real, but the company's realized magnitude remains unproven, which is precisely why C2 is priced as an option rather than a main driver.
Value chain and value distribution. Gross margins across R&D service segments form a "smile curve": commercial-stage CDMO highest (Asymchem small molecules 47.8%, WuXi chemicals adjusted gross margin 49-53%), laboratory discovery in the middle (Pharmaron 40-44%, WuXi biology 36.4%), clinical CRO/SMO lowest (Pharmaron 11%, Tigermed main business 21-27%). Pharmaron occupies an integrated position of "front-end R&D entry + back-end CDMO realization": 7,100+ laboratory chemistry researchers form one of the world's largest front-end teams; in 2025 small-molecule CDMO served 1,102 molecules (34 process validation/commercialization, 47 Phase III), and front-end lead generation → back-end funnel is the core value capture mechanism. But current value accumulation capability is weaker than WuXi's: TTM gross margin 33.8% vs WuXi 51.6%, Top 20 pharma revenue share 22.7% vs WuXi's roughly one-third or more, with customers dominated by the long tail of small/mid-cap biotechs—integration stickiness is its moat; single-point pricing power is not. Upstream (consumables/reagents/laboratory animals) is fully competitive, but primates for safety testing and high-end purification resins face periodic bottlenecks; downstream payers are global pharma R&D budgets plus financing, and Chinese innovative drug BD going overseas (2026Q1 out-licensing exceeded USD 60 billion, ~68% of global) has become a new source of demand.
Supply-demand and competitive landscape. Three demand engines: global pharma R&D spend + rising outsourcing penetration, financing recovery (2025 global innovative drug financing of about USD 61.8 billion, a three-year high; first three quarters of 2026 saw 343 domestic deals / about RMB 52.8 billion, annualized flat with 2025—a mild recovery, not a full boom), and new modality volume growth (GLP-1/ADC/oligonucleotides; WuXi TIDES 2025 revenue RMB 11.37 billion, +96%). On the supply side, after the 2023-2025 contraction, expansion has restarted: WuXi 2026 capex RMB 6.5-7.5 billion, Asymchem raised from RMB 2.1 billion to RMB 2.6-2.8 billion, Pharmaron above RMB 3 billion—the restart of the capacity race is itself the seed of 2027-2028 price risk (especially for peptide APIs). Competitive landscape: globally fragmented and tiered (clinical CRO Tier 1: IQVIA/LabCorp/ICON; small-molecule CRDMO led globally by WuXi at 3.5x Pharmaron's scale; large-molecule CDMO: Lonza/Samsung Biologics/WuXi Biologics), with China highly concentrated and concentration rising (WuXi alone accounted for 50.87% of total revenue and 82.93% of net profit attributable to shareholders in the 2026H1 sample of A-share CXO market cap TOP 20, Guolian Minsheng/Wind basis). Barriers to entry: compliance qualifications (FDA/EMA/NMPA GMP; Pharmaron's Ningbo/Shaoxing passed FDA PAI), talent density, customer switching costs, capital and process know-how. Price competition: domestic price wars were significant in 2023-2025, with an inflection in 2026 (Tigermed's new contract unit prices turned positive, low-price legacy orders cleared, industry "competition turning healthier"); CDMO price pressure is masked by surging orders—beware peptide API overcapacity after 2027. Substitution threat is low (in-housing suffers obvious cost disadvantages for pharma; AI drug discovery empowers rather than replaces).
Cycles and regulation. The industry is in the early stage of an upcycle: new orders (Pharmaron +30%+, Asymchem +54.6%, Tigermed +30%+, WuXi backlog RMB 66.43 billion +25.2%, all 2026 data) are recovering in tandem with leading indicators such as financing, capex, and research primate prices. Three regulatory threads: ① The US BIOSECURE Act became law on 2025-12-18—the final version names no companies, instead directing OMB to issue a BCC list within one year (by 2026-12-18) linked to the 1260H list, with roughly a five-year safe harbor for existing contracts and the ban limited to federal procurement/federal funding rather than commercial cooperation; as of 2026-10 WuXi entities were not on the effective 1260H list (added by the DoD in 2026-06, but a court preliminary injunction was obtained in August)—rule-based implementation has led to systematic convergence of the geopolitical discount that hung overhead for three years, but the list mechanism retains long-tail pressure; ② China's full-chain support for innovative drugs (2024-07 implementation plan, first Class B—丙类—drug list in 2025) improves the payment side; ③ In 2026-10, China's MOFCOM/MOST proposed adding CGT, small nucleic acids, etc. to the export control catalog but explicitly exempted CXO outsourcing services and License-out—official confirmation of the services trade channel amid two-way geopolitical games. Risk variables: the Fed hiked 25bp to 3.75-4.00% in 2026-09 (first since July 2023), 10-year US Treasury yield broke above 5.28%, CCC spreads above 1,000bp—if tightening persists, US biotech financing and Pharmaron's laboratory front-end demand (60% of revenue) will come under pressure.
Company positioning within the industry. Pharmaron is a second-tier leader in global integrated CRDMO and China's second integrated platform after WuXi AppTec (third-party brokers and media: second in China integrated CRDMO; the company describes itself as "a globally leading fully integrated CRDMO"—both framings presented side by side; the company's phrasing contains a self-descriptive element of "leading"). Share trend is upward: 2025 revenue RMB 14.095 billion (+14.8%), first three quarters +19.0%, consistently outpacing global industry growth (8-13%); MNC penetration accelerating (Top 20 pharma revenue +52.5% in the first three quarters, though the 22.7% share remains far below WuXi). Moats: integrated funnel (multi-segment cross-selling customers at 73.61%), globally compliant capacity (28 sites across China, UK, US, Singapore; strong FDA inspection record; overseas capacity hedging geopolitics), new modality positioning (Lilly chain). Weaknesses: labor efficiency (revenue per employee ~RMB 560,000 vs WuXi ~RMB 1.2 million), clinical segment gross margin (10.96%), large-molecule/CGT still in investment phase, relatively high interest-bearing debt. Characterization: mid-stage of the "order recovery → capacity ramp → profit realization" chain.
The decisive battleground for CXO lies not in conventional financial frameworks but in four trackable operating variables.
Backlog and new orders. Pharmaron's periodic reports disclose only the year-on-year growth of new orders (first three quarters +30%+: laboratory +25%+, CDMO +40%+, clinical +25%+), not absolute backlog amounts—a common disclosure weakness among CXOs and the core limitation of order metrics: unaudited, no currency/amount, no conversion-cycle disclosure. Historical calibration shows order growth and next-year revenue growth inverted twice (see C1); delivery rhythm is the dominant variable in revenue recognition. For tracking, cross-validate three variables: "new order growth + segment revenue growth + contract liabilities" (first three quarters contract liabilities RMB 1.225 billion, +27.5%, consistent with order direction).
Capacity and capex. Pharmaron's 2026 CapEx exceeds RMB 3 billion (RMB 2.206 billion already invested in the first three quarters), directed at: Shaoxing Phase I/II coming online successively, accelerated construction of Shaoxing Campus II and Hangzhou campus, peptide API solid-phase synthesis workshop completed in 2026, ADC/XDC late-stage capacity in production by 2027, and Beijing Campus III in use. Management explicitly stated "CDMO customer demand is strong and capacity is relatively tight"—capacity is the direct bottleneck in converting orders to revenue, and the key to whether CDMO's +40% orders can convert into 2027 revenue. Compliance qualifications are an implicit moat: Ningbo API workshop passed FDA on-site inspections twice in 2025-2026, and in 2026H1 passed the company's first pre-approval inspection for a China-innovated API. Risk side: the race between incremental depreciation on RMB 3 billion+ CapEx (estimated RMB 500-800 million per year) and utilization ramp-up, plus price divergence after industry-wide intensive peptide capacity additions (post-2027).
Overseas revenue and FX pass-through. Overseas revenue is 84.84% (FY2025: North America 61.82%, Europe 20.54%, China 15.16%), with roughly 90% of costs denominated in RMB—RMB appreciation passes through in three ways: revenue translation, FX gains/losses, and gross margin. Already realized in the first three quarters: finance costs RMB 308 million (+100.98%), Non-IFRS FX-related losses RMB 169 million (vs RMB 31 million a year earlier), laboratory gross margin -2.4pct, foreign currency translation difference -RMB 221 million. Sensitivity (our estimate, assuming ~50% hedge coverage): a further 3% RMB appreciation implies revenue -0.9~-1.9pct, gross margin -1.5~-1.7pct, net profit attributable -8~-13%. At present, the RMB's direction is tied to the Fed's tightening path, making it one of the largest swing factors in 2027 earnings forecasts.
Labor efficiency and AI/automation. Revenue per employee ~RMB 562,000 (FY2025, slightly down YoY) vs WuXi ~RMB 1.2 million—the structurally high density of front-end laboratory labor and low share of back-end commercialization are the causes, but the gap itself points to a profit ceiling. The industry is in the early stage of AI/automation reshaping the cost curve (Tigermed's AI medical writing cuts labor by 40-60%; Pharmaron advancing AI and automation integration), and the speed of labor-efficiency convergence will determine whether Pharmaron's gross margin gap versus WuXi can narrow.
Overall rating: Neutral, confidence 0.55, time horizon 6-12 months. Pharmaron is a company with "fundamentals improving, price already there": the inflection in orders and revenue is supported by A-grade evidence, the Lilly GLP-1 partnership and peptide capacity provide a real option, and management guidance has been raised and is being delivered; but a 36.4x TTM adjusted PE and 4.52x PB have already priced the baseline recovery into the current price. Margin of safety is about -3.3%, expected return about -2%, with odds more sensitive to the bear case (-47%~-57%) than the bull case (+16%~+38%). Holders can continue holding and watch the falsification lines; a better entry point for new capital is likely after pullbacks triggered by BCC list event反复—triggered by BCC list event back-and-forth, unlock supply, or macro shocks.
Strategy points: ① Upside trigger—a break above RMB 46 (upper bound of baseline fair value) would mean the market has begun pricing the bull case; reassess whether upside remains; ② Downside trigger—a break below RMB 30 puts the stock on the bear-case validation path, requiring re-examination of BCC and order variables; ③ Fundamental falsification lines—Pharmaron added to the BCC/1260H lists, two consecutive quarters of negative North America revenue growth, new order growth falling below +10%, combined laboratory+CDMO gross margin below 30%, or goodwill impairment above RMB 500 million—any one triggers a re-rating.
Key milestones and monitoring checklist for the next 6-12 months:
Key monitoring: ① Composition of the BCC list and federal procurement rules (statutory deadline 2026-12-18)—the largest binary event; ② 2026 annual report: whether full-year revenue reaches the upper half of 15-20%, CDMO gross margin YoY, 2027 guidance, goodwill test parameters; ③ orforglipron's NMPA review status in China and substantive disclosure of the Lilly contract (amounts/minimum guarantees); ④ quarterly new order growth and North America revenue growth (+30%/+10.1% as baseline); ⑤ peptide solid-phase synthesis workshop commissioning and utilization; ⑥ RMB exchange rate and quarterly FX losses (a warning if a single quarter exceeds RMB 80 million); ⑦ convertible bond resolution path (conversion price HKD 36.08 vs current H-share price).
This report is based on public information as of 2026-11-01; the price anchor is the 2026-10-30 closing price of RMB 41.37. Data marked "our estimate" in this report are inferences based on public disclosures; all other financial data carry cited sources.